novo nordisk glp-1 asks FDA to prevent compounders from making knockoffs GLP-1 analogs, new trend in

With the participation of researchers from the Paul Langerhans Institute Dresden (PLID), partner at the German Center for Diabetes Research, a GLP-1 receptor agonist in the form of tablets could for the first time be compared with the most common second-line therapy of T2D, a DPP-IV inhibitor

The GLP-1 Analogues Market estimated size and share is projected to exceed USD 322.85 Billion by 2034, with a forecasted CAGR of 21.3% during the period.

Even though India prohibits direct-to-consumer marketing of prescription drugs, regulators are watching out for messaging to induce misuse

Firmly apply to your skin and wear for 8 hours